The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria
Open accessAbstract
-antihistamine treatment. Omalizumab binds to free IgE, which lowers free IgE levels and causes FcεRI receptors on basophils and mast cells to be downregulated. It has been shown to improve symptoms of CIU/CSU, but its mechanism of action is not currently understood. Potential mechanisms in CIU/CSU include reducing mast cell releasability, reversing basopenia and improving basophil IgE receptor function, reducing activity of IgG autoantibodies against FcεRI and IgE, reducing activity of IgE autoantibodies against an antigen or autoantigen that has yet to be definitively identified, reducing the activity of intrinsically 'abnormal' IgE, and decreasing in vitro coagulation abnormalities associated with disease activity. However, none of these theories alone or in combination fully account for the pattern of symptom improvement seen with omalizumab therapy, and therefore, no one mechanism is likely to be the definitive mechanism of action. Additional research is needed to further clarify the involvement of omalizumab in relieving symptoms associated with the complex, multifactorial pathogenesis of CIU/CSU.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zuberbier, T., Aberer, W., Asero, R., Bindslev‐Jensen, C., Brzoza, Z., Canonica, G. W., Church, M. K., Ensina, L. F., Giménez‐Arnau, A., Godse, K., et al. (2014) · Allergy · doi:10.1111/all.12313 · Cited by 1,203
Self-citationOmalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria
Maurer, M., Rosén, K., Hsieh, H.-J., Saini, S., Grattan, C., Gimenéz-Arnau, A., Agarwal, S., Doyle, R., Canvin, J., Kaplan, A., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215372 · Cited by 1,105
Self-citationHide, M., Francis, D. M., Grattan, C., Hakimi, J., Kochan, J. P., & Greaves, M. W. (1993) · New England Journal of Medicine · doi:10.1056/nejm199306033282204 · Cited by 895
Maurer, M., Weller, K., Bindslev-Jensen, C., Giménez-Arnau, A., Bousquet, P. J., Bousquet, J., Canonica, G. W., Church, M. K., Godse, K. V., Grattan, C. E. H., et al. (2011) · Allergy · doi:10.1111/j.1398-9995.2010.02496.x · Cited by 843
Self-citationMacGlashan, D. W., Bochner, B. S., Adelman, D. C., Jardieu, P. M., Togias, A., McKenzie-White, J., Sterbinsky, S. A., Hamilton, R. G., & Lichtenstein, L. M. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.3.1438 · Cited by 823
The diagnosis and management of acute and chronic urticaria: 2014 update
Bernstein, J. A., Lang, D. M., Khan, D. A., Craig, T., Dreyfus, D., Hsieh, F., Sheikh, J., Weldon, D., Zuraw, B., Bernstein, D. I., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.02.036 · Cited by 682
Kaplan, A., Ledford, D., Ashby, M., Canvin, J., Zazzali, J. L., Conner, E., Veith, J., Kamath, N., Staubach, P., Jakob, T., et al. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.05.013 · Cited by 573
Self-citationThe late phase of the immediate wheal and flare skin reaction. Its dependence upon IgE antibodies.
Solley, G. O., Gleich, G. J., Jordon, R. E., & Schroeter, A. L. (1976) · Journal of Clinical Investigation · doi:10.1172/jci108485 · Cited by 542
Humanization of an antibody directed against IgE.
Presta, L. G., Lahr, S. J., Shields, R. L., Porter, J. P., Gorman, C. M., Fendly, B. M., & Jardieu, P. M. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.5.2623 · Cited by 474
Saini, S. S., Bindslev-Jensen, C., Maurer, M., Grob, J.-J., Bülbül Baskan, E., Bradley, M. S., Canvin, J., Rahmaoui, A., Georgiou, P., Alpan, O., et al. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.306 · Cited by 471
Self-citation
Cited by
Kolkhir, P., Giménez-Arnau, A. M., Kulthanan, K., Peter, J., Metz, M., & Maurer, M. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00389-z · Cited by 382
Self-citationOmalizumab therapy for mast cell-mediator symptoms in patients with ISM, CM, MMAS, and MCAS
Lemal, R., Fouquet, G., Terriou, L., Vaes, M., Livideanu, C. B., Frenzel, L., Barete, S., Canioni, D., Lhermitte, L., Rossignol, J., et al. (2019) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2019.03.039 · Cited by 70
The evolving atopic dermatitis management landscape
Sahni, V. N., Balogh, E. A., Strowd, L. C., & Feldman, S. R. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1999412 · Cited by 20
Metadata
- Authors
- Kaplan, A. P., Giménez-Arnau, A. M., & Saini, S. S.
- Venue
- Allergy
- Publisher
- Wiley
- Published
- 2017-01-04
- Volume
- 72
- Issue
- 4
- Pages
- 519-533
- ISSN
- 0105-4538 (ISSN-L)
- OpenAlex
- W2556598798
- Cited by
- 293
- References
- 100
- FWCI
- 21.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. https://app.cochat.ai/papers/10.1111/all.13083
- The paper
- Kaplan, A. P., Giménez-Arnau, A. M., & Saini, S. S. (2017). Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy. https://doi.org/10.1111/all.13083
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
